A new drug for rare diseases: pozelimab for CHAPLE disease
- PMID: 38278169
- DOI: 10.1016/S0140-6736(23)02652-1
A new drug for rare diseases: pozelimab for CHAPLE disease
Conflict of interest statement
AB reports consulting fees from Kabi, Roche Chugai, GlaxoSmithKline, AbbVie, Novartis, and Boehringer Ingelheim; research grants from Boehringer Ingelheim, ANR, and Horizon Europe outside the scope of this Comment; and is an unpaid co-chair of the French National Network on Rare Autoimmune and Autoinflammatory Diseases. All other authors declare no competing interests.
Comment on
-
Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.Lancet. 2024 Feb 17;403(10427):645-656. doi: 10.1016/S0140-6736(23)02358-9. Epub 2024 Jan 23. Lancet. 2024. PMID: 38278170 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical